Effect of Repeated Intravenous Esketamine on Adolescents with Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.
Yanling Zhou,Xiaofeng Lan,Chengyu Wang,Fan Zhang,Haiyan Liu,Ling Fu,Weicheng Li,Yanxiang Ye,Zhibo Hu,Ziyuan Chao,Yuping Ning
DOI: https://doi.org/10.1016/j.jaac.2023.05.031
IF: 13.113
2023-01-01
Journal of the American Academy of Child & Adolescent Psychiatry
Abstract:Objective: Suicide is a major cause of death in adolescents with limited treatment options. Ketamine and its enantiomers have shown rapid antisuicidal effects in adults with major depressive disorder (MDD), but their efficacy in adolescents is unknown. We conducted an active, placebocontrolled trial to determine the safety and efficacy of intravenous esketamine in this population. Method: A total of 54 adolescents (aged 13-18 years) with MDD and suicidal ideation were included from an inpatient setting and randomly assigned (1:1) to receive 3 infusions of esketamine (0.25 mg/kg) or midazolam (0.02mg/kg) over 5 days, with routine inpatient care and treatment. Changes from baseline to 24 hours after the final infusion (day 6) in the scores of the Columbia Suicide Severity Rating Scale (C-SSRS) Ideation and Intensity (primary outcome) and the Montgomery - Asberg Depression Rating Scale (MADRS, key secondary outcome) were analyzed using linear mixed models. In addition, the 4 -week clinical treatment response was a key secondary outcome. Results: The mean changes in C-SSRS Ideation and Intensity scores from baseline to day 6 were significantly greater in the esketamine group than in the midazolam group (Ideation, - 2.6 [SD = 2.0] vs - 1.7 [SD = 2.2], p = .007; Intensity, - 10.6 [SD = 8.4] vs - 5.0 [SD = 7.4], p = .002), and the changes in MADRS scores from baseline to day 6 were significantly greater in the esketamine group than in the midazolam group (-15.3 [SD = 11.2] vs - 8.8 [SD = 9.4], p = .004). The rates of antisuicidal and antidepressant responses at 4 weeks posttreatment were 69.2% and 61.5% after esketamine, and were 52.5% and 52.5% after midazolam, respectively. The most common adverse events in the esketamine group were nausea, dissociation, dry mouth, sedation, headache, and dizziness. Conclusion: These preliminary findings indicate that 3-dose intravenous esketamine, added to routine inpatient care and treatment, was an effective and well-tolerated therapy for treating adolescents with MDD and suicidal ideation. Diversity & Inclusion Statement: We worked to ensure that the study questionnaires were prepared in an inclusive way. The author list of this paper includes contributors from the location and/or community where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work. We actively worked to promote sex and gender balance in our author group.